Skip to main content
. 2013 Oct 17;109(10):2654–2664. doi: 10.1038/bjc.2013.606

Figure 7.

Figure 7

Expression and activity of HSF1 in human non-tumourous liver and hepatocellular carcinomas (HCC). HCC were divided in two categories based on patient survival length after partial liver resection: HCC with survival >3 years (HCCB), and HCC with survival <3 years (HCCP). (A) Representative western blot analysis of HSF1 and its activated/phosphorylated form at serine 326 (Ser326). Hepatic tissue lysates were subjected to western blotting with specific antibodies. (B) Chemiluminescence analysis: optical densities of the peaks were normalised to β-actin values and expressed in arbitrary units. (C) HSF1 mRNA levels were determined by quantitative RT–PCR. N Target (NT)=2−ΔCt; ΔCt=Ct RNR18 - Ct target gene. (D) Specific activity of HSF1: ng/ml of HSF1 (pSer326). Data are means (s.d.) of six normal livers (NL), 30 HCCB and 32 HCCP, and corresponding surrounding livers (SL) with better or poorer prognosis. Dot: different from NL for at least P=0.003; asterisk: different from SL for P<0.0001; dagger: different from SLB and HCCB for P<0.0001. (E) Relationships between HSF1 and DNA-PKcs-specific activity (SA) in HCCs.